[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360133-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360133-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","local-immunotherapy-for-the-treatment-of-cancer-scientific-advances-and-clinical-potential","Local immunotherapy for the treatment of cancer: scientific advances and clinical potential","","Local immunotherapy can deliver high doses of immune-activating agents directly to a tumor while limiting systemic toxicity, yet clinical translation has faced major obstacles. The article introduces a planned Journal for ImmunoTherapy of Cancer series to address the promise of local immunotherapy and provide guidance to overcome current barriers in local drug development. It discusses key concepts, including in situ vaccination, retained drug exposure, and expanding local immunity systemically.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/local-immunotherapy-for-the-treatment-of-cancer-scientific-advances-and-clinical-potential/360133/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/local-immunotherapy-for-the-treatment-of-cancer-scientific-advances-and-clinical-potential/360133.png","ImageObject",300,407,{"name":42,"@type":43},"Nguyễn Văn Học","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is local immunotherapy and why is it promising?","Question",{"text":63,"@type":64},"Local immunotherapy delivers immune-modulating agents directly into a localized site, such as by intralesional/intratumoral injection, or via activation in the tumor microenvironment. It can enable high local dosing with limited systemic exposure and toxicity while supporting specific antitumor immune responses, including an in situ “vaccination effect.”","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What therapeutic strategies are highlighted as prototype approaches?",{"text":68,"@type":64},"Oncolytic viruses are described as the prototypical local immunotherapy, with talimogene laherparepvec as an example approved for intratumoral melanoma after initial surgery. The document also notes expanding strategies beyond viruses, including chemotherapy, nucleic acids, antibodies, proteins, cells, non-oncolytic viruses, and local ablation methods such as focused ultrasound, hyperthermia, irreversible electroporation, and cryotherapy.",{"name":70,"@type":61,"acceptedAnswer":71},"How will the journal series address challenges in local immunotherapy development?",{"text":72,"@type":64},"After a SITC summit focused on intralesional immunotherapy, the article states that the journal will address five key questions over the next year via minireviews, commentary/perspective articles, and consensus papers. These cover enhancing in situ vaccination, identifying promising local approaches and clinical design needs, integrating into combination regimens, assessing roles in neoadjuvant treatment, and defining major research and drug-development priorities.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360133,1790777091,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":30,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":111,"preview_page_count":30,"preview_urls":144},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","Open access Editorial  \n Local immunotherapy for the treatment  \nof cancer: scientific advances and clinical potential  \nHoward L Kaufman  ,1 Tanja D de Gruijl2  \nTo cite: Kaufman HL, de Gruijl TD. Local immunotherapy for the treatment of cancer: scientific advances and clinical potential. Journal for ImmunoTherapy of Cancer 2026;14:e015469 . doi:10 . 1136/ jitc-2026-015469  \nAccepted 20 April 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA 2Departments of Medical Oncology & Radiation Oncology, Cancer Center Amsterdam, University Medical Center Amsterdam, Amsterdam, The Netherlands  \nCorrespondence to  \nDr Howard L Kaufman;  \n[HLKaufman@mgh.harvard.edu](HLKaufman@mgh.harvard.edu)  \nABSTRACT  \nLocal immunotherapy has the potential to deliver high doses of immune-potentiating agents with limited systemic toxicity. However, clinical development and implementation have been hindered by numerous challenges. Journal for ImmunoTherapy of Cancer will be addressing the potential promise of local immunotherapy and providing guidance on how to overcome current challenges in local drug development through a series of special reports over the next year.  \nLocal immunotherapy is a conceptual therapeutic approach to treating disease that involves the delivery and retention of immune-modulating agents directly into a specific, localized site,1 achieved, for example, by direct injection of a tumor (that is, intralesional or intratumoral) or by systemic administration in which the active pharmacologic agent is activated within the tumor microenvironment. Theoretical advantages of local immunotherapy include the potential to deliver higher doses of pharmacologic agents that induce immunogenic tumor cell death and/or activate local immune responses utilizing local tumor-associated antigens to drive highly specific antitumor immunity, aso-called in situ “vaccination effect.”1 Further, if the active drug is retained at the tumor site, there is limited systemic exposure and less systemic toxicity. Local immunity can be expanded into a systemic host antitumor immune response that can mediate regression of distant disease by “abscopal” or, more appropriately, ananestic responses.2 Despite the promise of local immunotherapy, there have been considerable challenges in clinical development and commercialization.  \nOncolytic viruses represent the prototypical local immunotherapy. Talimogene laherparepvec is an oncolytic herpes virus, type 1, encoding granulocyte-macrophage colony stimulating factor (GM-CSF), and was approved for intratumoral treatment of melanoma that recurs after initial surgery in 2015.3 The field has been expanding beyond  \noncolytic viruses, with an increasing number of pharmacologic and mechanical strategies.1 2 In addition to oncolytic viruses, cytotoxic chemotherapy, nucleic acids, antibodies, proteins, cells, and non-oncolytic viruses have all been proposed for local cancer therapy. Further, local ablation therapies involving (mechanical) manipulation of tumors, as by focused ultrasound, hyperthermia, irreversible electroporation, and cryotherapy, have also shown therapeutic promise, serving asa means of immune modulation and in-vivo vaccination, in both preclinical tumor models and early clinical trials.2  \nOn September 19, 2024, the Society for Immunotherapy of Cancer (SITC) sponsored a global summit, titled “SITC Summit on Intralesional Immunotherapy: Moving Beyond Oncolytic Viruses” ([https://www](https://www). [sitcancer.org/viewdocument/sitc-summit-on](sitcancer.org/viewdocument/sitc-summit-on)intralesional-immuno) . This summit brought together leading experts in the field to identify the benefits and challenges of local immunotherapy, and define the research agenda needed to realize the full impact of local immunotherapy. Participants a","cbCain7DnpIZpv9f","https://ap.wps.com/l/cbCain7DnpIZpv9f","pdf",196185,"English","# Abstract\n## Local immunotherapy concept and advantages\n## Main local therapeutic approaches\n## SITC summit and research agenda\n## Key scientific issues and challenges\n### In situ vaccination against cancer\n### Promising local approaches and clinical design advances\n### Integration into combination regimens\n### Role in neoadjuvant treatment\n### Priorities for research and drug development","[{\"question\":\"What is local immunotherapy and why is it promising?\",\"answer\":\"Local immunotherapy delivers immune-modulating agents directly into a localized site, such as by intralesional/intratumoral injection, or via activation in the tumor microenvironment. It can enable high local dosing with limited systemic exposure and toxicity while supporting specific antitumor immune responses, including an in situ “vaccination effect.”\"},{\"question\":\"What therapeutic strategies are highlighted as prototype approaches?\",\"answer\":\"Oncolytic viruses are described as the prototypical local immunotherapy, with talimogene laherparepvec as an example approved for intratumoral melanoma after initial surgery. The document also notes expanding strategies beyond viruses, including chemotherapy, nucleic acids, antibodies, proteins, cells, non-oncolytic viruses, and local ablation methods such as focused ultrasound, hyperthermia, irreversible electroporation, and cryotherapy.\"},{\"question\":\"How will the journal series address challenges in local immunotherapy development?\",\"answer\":\"After a SITC summit focused on intralesional immunotherapy, the article states that the journal will address five key questions over the next year via minireviews, commentary/perspective articles, and consensus papers. These cover enhancing in situ vaccination, identifying promising local approaches and clinical design needs, integrating into combination regimens, assessing roles in neoadjuvant treatment, and defining major research and drug-development priorities.\"}]","Local immunotherapy for the treatment of cancer: scientific advances and clinical potential | PDF",1790138841,[145,149,153],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64f8d5a44655e003427dda2b4e47eca6.webp",983,1310,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/361bd1eda61e9c92cf738f3f5e12c8eb.webp",982,1309,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/253c9efdd09c5235f080ab904aa39158.webp",981,1308]